ClinicalTrials.gg
CompletedNCT00143286Updated Jun 4, 2007

A 52-Week Multicenter Study Evaluating the Safety and Efficacy of Varenicline for the Maintenance of Smoking Cessation

A Phase 3 interventional study of varenicline (CP-526,555) in Smoking Cessation, sponsored by Pfizer. Completed at 24 sites in 7 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2007-06-04.

Sponsored by Pfizer · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
2,000
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 110 studies testing varenicline in Smoking Cessation — 5 open to participants now, 7 under way, 2 of them phase 3. Varenicline · Smoking Cessation.

Enrollment
3rd of 110
2,000 · median 209
Started
2003
with 3 others
Phase 3
24 of 110
1 open now
Registered
4th of 110
by date
Lead sponsor
26 of 110
Pfizer

Among the 110 studies testing varenicline in Smoking Cessation, this one is the 3rd largest by enrollment, is one of 4 that started in 2003, is one of 24 in phase 3, and was the 4th registered.

Smoking Cessation

1,582 studies on the registry are indexed under Smoking Cessation; 198 are open to participants now.

Browse Smoking Cessation studies →

Open to participants now

5 of the 110 studies testing varenicline in Smoking Cessation are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About varenicline

Varenicline: first FDA approval 2006 (CHANTIX), first EMA approval 2006. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 137 Smoking Cessation studies recruiting now, 93 (68%) set no upper age limit and 37 (27%) stop at 75 or younger; 6 take children under 18; 41 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 110 studies testing varenicline in Smoking Cessation, or all of them as a file.
02

Study summary

The primary purpose of this study is a comparison of abstinence maintenance in subjects randomized to double-blind varenicline or placebo from Weeks 13 -24 in subjects who responded to an intial 12-week open label course of varenicline, with post-treatment follow-up of smoking status to Week 52.

03

Conditions studied

  • Smoking Cessation

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects must have smoked an average of at least 10 cigarettes per day during the past year and over the month prior to the screening visit, with no period of abstinence greater than 3 months in the past year.

Exclusion criteria

Exclusion Criteria:

  • Subjects with cardiovascular disease in the past 6 months.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double
Enrollment
2,000 participants

Interventions

06

What researchers measure

Primary outcomes

  1. Continuous abstinence Weeks 13 -24.

Secondary outcomes

  1. Continuous abstinence Weeks 13-52

  2. Long term quit rate at Week 52

  3. 7-day Point Prevalence of abstinence at Weeks 24, 52

  4. 4-week Point Prevalence of abstinence at Week 52

  5. Time to first cigarette post randomization

07

Study locations

24 sites
  • Pfizer Investigational Site
    Santa Ana, California, United States
  • Pfizer Investigational Site
    West Palm Beach, Florida, United States
  • Pfizer Investigational Site
    Lexington, Kentucky, United States
  • Pfizer Investigational Site
    Mogadore, Ohio, United States
  • Pfizer Investigational Site
    Dallas, Texas, United States
  • Pfizer Investigational Site
    Seattle, Washington, United States
  • Pfizer Investigational Site
    Calgary, Alberta, Canada
  • Pfizer Investigational Site
    Halifax, Nova Scotia, Canada
  • Pfizer Investigational Site
    Ottawa, Ontario, Canada
  • Pfizer Investigational Site
    Toronto, Ontario, Canada
  • Pfizer Investigational Site
    Cornwall, Prince Edward Island, Canada
  • Pfizer Investigational Site
    Sherbrooke, Quebec, Canada
  • Pfizer Investigational Site
    Prague 2, Czech Republic
  • Pfizer Investigational Site
    Hellerup, Copenhagen, Denmark
  • Pfizer Investigational Site
    Aarhus C, Denmark
  • Pfizer Investigational Site
    Frederikssund, Denmark
  • Pfizer Investigational Site
    Bergen, Norway
  • Pfizer Investigational Site
    Honefoss, Norway
  • Pfizer Investigational Site
    Oslo, Norway
  • Pfizer Investigational Site
    Göteborg, Sweden
  • Pfizer Investigational Site
    Helsingborg, Sweden
  • Pfizer Investigational Site
    Stockholm, Sweden
  • Pfizer Investigational Site
    London, Surrey, United Kingdom
  • Pfizer Investigational Site
    London, United Kingdom
08

References and documents

Publications

  • Hajek P, Tonnesen P, Arteaga C, Russ C, Tonstad S. Varenicline in prevention of relapse to smoking: effect of quit pattern on response to extended treatment. Addiction. 2009 Sep;104(9):1597-602. doi: 10.1111/j.1360-0443.2009.02646.x. PubMed 19686530 ↗
  • Tonstad S, Tonnesen P, Hajek P, Williams KE, Billing CB, Reeves KR; Varenicline Phase 3 Study Group. Effect of maintenance therapy with varenicline on smoking cessation: a randomized controlled trial. JAMA. 2006 Jul 5;296(1):64-71. doi: 10.1001/jama.296.1.64. PubMed 16820548 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2003 and a completion of Mar 2005. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 31, 2005
First posted
Sep 2, 2005
Start
Apr 2003
CompletionActual
Mar 2005
Last update
Jun 4, 2007
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 4, 2007, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00143286
Lead sponsor
Pfizer
First posted
Sep 2, 2005
Start date
Apr 2003
Completion
Mar 2005
Last update
Jun 4, 2007

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2007. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Varenicline

Start the discussion